Xoma Royalty Corporation recently made headlines with its strategic moves to acquire struggling biotechnology companies, HilleVax and Lava Therapeutics. These acquisitions come at a time when both companies have faced challenges since their initial public offerings, trading below their cash holdings. Xoma’s acquisition of HilleVax includes a deal offering $1.95 per share to investors along with additional rights to cash holdings, potential savings on a building lease, and a share of proceeds from the sale of HilleVax’s vaccine programs. On the other hand, the acquisition of Lava involves a payment of at least $1.16 per share with a contingent value right tied to program proceeds and asset sales.
HilleVax, which went public in 2022, aimed to develop a vaccine for acute gastroenteritis but faced a significant decline in value following disappointing trial results. The company had to make tough decisions like halting its lead program, reducing staff, and exploring strategic alternatives. Meanwhile, Lava Therapeutics, known for its development of gamma delta T cell engagers for cancer, underwent a restructuring process that included laying off staff due to setbacks in its lead program study results. Xoma’s CEO, Owen Hughes, believes that the acquisition structures for both HilleVax and Lava have the potential to benefit shareholders in the long run.
The acquisitions of HilleVax and Lava reflect a trend of distressed biotech companies, often referred to as “biotech zombies,” facing pressure to restructure or seek buyout deals. Xoma’s moves parallel those of Concentra Biosciences, which has been actively acquiring distressed biotechs like Cargo Therapeutics and Elevation Oncology. The biopharma industry is witnessing a growing interest in such acquisitions, with players like KKR and Alis Biosciences also exploring similar business models. Furthermore, venture investors like OrbiMed are stepping in with new funding strategies to support struggling startups, indicating a broader effort to revitalize the biotech sector.
Xoma’s acquisition strategy sheds light on the broader landscape of the biopharma industry, where distressed biotechs present opportunities for consolidation and revitalization. The company’s focus on acquiring struggling firms like HilleVax and Lava underscores a trend of consolidation and restructuring in the sector. As Xoma navigates these acquisitions, industry observers are keenly watching how these deals will unfold and whether they will indeed benefit shareholders in the long term. The biopharma space continues to evolve rapidly, with companies exploring innovative strategies to address challenges and capitalize on emerging opportunities.
Key takeaways:
– Xoma’s recent acquisitions of HilleVax and Lava highlight a trend of distressed biotechs being targeted for consolidation.
– The biopharma industry is witnessing an increase in acquisitions of struggling companies, reflecting a broader effort to revitalize the sector.
– Xoma’s acquisition strategy aligns with a trend of companies seeking to restructure and capitalize on opportunities presented by distressed biotechs.
– Venture investors are also playing a crucial role in supporting struggling startups through innovative funding approaches.
Read more on biopharmadive.com